Treatment of vestibular vertigo with Vertidisan - Longitudinal trial

Treatment of vestibular vertigo with Vertidisan - Longitudinal trial - RCT VH-90-D long

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030712

Enrollment

180

Registered

2023-09-06

Start date

2022-10-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H81

Interventions

Group 1: Vertidisan Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Vestibular vertigo

Exclusion criteria

Exclusion criteria: Severe bone disease Severe internal disease Severe neurological disease Central vertigo Severe visual disorder No German language

Design outcomes

Primary

Measure	Time frame
VSS-sf-VER Score; Questionaire at T0 and after 12, 24 and 48 weeks	—

Secondary

Measure	Time frame
QoL SF36, DHI, CGI-I, CGI-S, Stress thermometer, VSS-sf-AA	—

Countries

Germany

Contacts

Public ContactHans P. Zenner

Clinical Research Organization

office@hpzenner.de+49 7071 793 61 63

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026